Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
· One complete response (CR) and two partial responses (PR) observed for the nine patients in part 1 (33% ORR), who received only three ONCOS-102 injections · Innate and adaptive immune activation observed in nine out of nine patients Oslo, Norway, 8 July, 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that clinical responses were observed in 3 out of 9 patients in part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 checkpoint inhibitor (CPI) refractory advanced